Eyesiu Medicines BV

Eyesiu Medicines BV, founded in 2014 and based at the Leiden Bio Science Park in the Netherlands, specializes in the development of innovative therapeutics and nutraceuticals. The company leverages advanced nanotechnology, specifically proprietary PEGylated lipid nanoparticle delivery technology, to improve the efficacy and delivery of existing therapeutics and body-own molecules. This technology allows for the creation of solvent-free, stable formulations that can be administered via various routes, including intranasal, ocular, dermal, and inhalation, targeting inflammatory processes across neurology, ophthalmology, dermatology, and pulmonology. The company differentiates its approach by using this platform to enhance the performance of established compounds for broader clinical applications.

These advancements are significant for addressing chronic inflammatory disorders and improving patient quality of life. By optimizing the delivery of molecules like cyclosporine A and palmitoylethanolamide (PEA), Eyesiu aims to provide more effective treatments for conditions affecting the brain, eyes, lungs, skin, and hair. In addition to its preclinical pharmaceutical pipeline, the company operates a consumer healthcare division, Eyesiu Care, which offers nutraceutical products like the PEArlboost+ spray. Eyesiu continues to expand its intellectual property portfolio through international patent grants for its lipid particle formulas and actively explores product partnerships to further its research and development initiatives.